NEWS & UPDATES

Gliprons are a new class of non-peptide, small-molecule, oral GLP-1 receptor agonists used for treating type 2 diabetes and obesity. This shift from "Large Molecule/Biologic" to "Small Molecule/Chemical" changes everything: Easier Synthesis: They are produced via standard chemical synthesis rather than complex biological fermentation or solid-phase peptide synthesis (SPPS). No Cold Chain: Because they are chemically stable, they don’t require the expensive refrigerated shippi

Molecular Glue Degraders (MGDs) are emerging as one of the most promising advances in drug development, offering a way to target many previously "undruggable" disease-causing proteins. Unlike traditional small molecules that rely on specific binding pockets, MGDs enhance interactions between a target protein and an E3 ubiquitin ligase, triggering the protein's degradation through the cell's natural ubiquitin-proteasome system. Another important class is PROTACs, which use a b

The weight loss and diabetes drug revolution is moving faster than almost any other sector in healthcare. We’ve seen the massive market disruption caused by single-target medications like (Semaglutide). Next came dual-target molecules (like Tirzepatide), and currently moving through trials are triple-target therapies. Now, the scientific frontier has officially shifted to "Quintuple Agonists"—a single molecule engineered to hit five separate metabolic targets at the exact sam

While JAK1-3 inhibitors have been powerful tools against inflammation, their broad systemic footprint has always been a double-edged sword. The industry's answer? Selective TYK2 inhibition. By precision-blocking the TYK2 enzyme, these small molecules deliver targeted relief for plaque psoriasis and psoriatic arthritis, bypassing the pathways that trigger severe systemic side effects. But for those of us bridging the gap between patent law and chemical procurement, the real st

The Next Frontier in Hypertension: Aldosterone Synthase Inhibitors (ASIs) The landscape for treating resistant hypertension and Chronic Kidney Disease (CKD) is shifting. While Mineralocorticoid Receptor Antagonists (MRAs) have long been the standard, a new class of therapeutics is stepping into the spotlight: Aldosterone Synthase Inhibitors (ASIs). With the FDA's anticipated 2026 decisions on Baxdrostat and Lorundrostat, the "Patent Thicket" around Aldosterone Synthase Inhibi

This week Linkedin is full with the news of Pfizer settlement with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (Tafamidis). While three major players have settled, Apotex remains a notable name still navigating the litigation waters. The industry is watching closely to see if they will hold out for a different ou

Phosphodiesterase-4 (PDE4) is an enzyme responsible for breaking down cyclic adenosine monophosphate (cAMP). When we inhibit this enzyme: cAMP levels rise, effectively "turning down the volume" on the body's inflammatory response. This suppression happens across immune, epithelial, and brain cells, making it a versatile therapeutic target. PDE4 inhibitors are already transforming lives in several key areas: Respiratory Health: Managing Chronic Obstructive Pulmonary Disease (C

Semaglutide: The core molecule is now off-patent in India (as of March 20th) BUT the US and EU markets remain locked behind "Patent Thickets" until many years. The biggest risk for firms today isn't only the science, but also the Legal + Supply Chain overlap. I can help your company navigate this by providing: ✅ IP Due Diligence: Auditing your FTO so you don't trip over device or SNAC patents. ✅ Verified Sourcing: Connecting you with top-tier API/Intermediate manufacturers (S